Valuation: Vitrolife AB

Market Cap 11.78B 1.22B 1.07B 995M 914M 1.72B 117B 1.76B 4.6B 57.99B 4.59B 4.49B 201B P/E 2026 *
23.9x
P/E 2027 * 19.3x
Enterprise Value 12.33B 1.28B 1.11B 1.04B 957M 1.8B 122B 1.84B 4.82B 60.69B 4.8B 4.7B 211B EV / Sales 2026 *
3.57x
EV / Sales 2027 * 3.17x
Free-Float
54.39%
Yield 2026 *
1.27%
Yield 2027 * 1.45%
Manager TitleAgeSince
Chief Executive Officer 52 2023-07-31
Director of Finance/CFO 55 2025-10-09
Chief Investment Officer 39 -
Director TitleAgeSince
Director/Board Member 63 2013-04-18
Chairman 70 2023-07-31
Chairman 55 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.68% - - 1.21B
+0.31%-5.40%+225.43%+271.12% 19.04B
-2.80%+3.48%-41.63%-25.88% 10.07B
-2.57%-7.36%+38.10%+13.70% 6.68B
-1.55%-1.86%+216.39%-26.37% 5.97B
+0.31%+4.14%-15.57%-20.65% 5.53B
0.00%-0.89%-42.39% - 4.41B
0.00%+5.10%-21.46%-30.05% 4.26B
-0.33%-16.23%+70.56%+88.36% 4.15B
+2.54%+0.15%-18.58%-43.19% 2.69B
Average -0.39%-0.86%+45.65%+28.38% 6.98B
Weighted average by Cap. -0.63%-1.49%+84.36%+82.94%

Financials

2026 *2027 *
Net sales 3.46B 359M 313M 292M 268M 504M 34.3B 516M 1.35B 17.02B 1.35B 1.32B 59.06B 3.71B 384M 335M 313M 288M 540M 36.78B 553M 1.45B 18.25B 1.44B 1.41B 63.33B
Net income 493M 51.08M 44.53M 41.58M 38.21M 71.74M 4.89B 73.43M 192M 2.42B 192M 188M 8.41B 609M 63.13M 55.03M 51.39M 47.23M 88.67M 6.04B 90.76M 238M 3B 237M 232M 10.4B
Net Debt 549M 56.94M 49.64M 46.35M 42.59M 79.98M 5.45B 81.86M 215M 2.7B 214M 209M 9.38B -26.74M -2.77M -2.42M -2.26M -2.07M -3.89M -265M -3.99M -10.45M -132M -10.41M -10.19M -457M
Logo Vitrolife AB
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-